Analyst Ratings for Coherus BioSciences
Portfolio Pulse from Benzinga Insights
Coherus BioSciences (NASDAQ:CHRS) has received positive analyst ratings in the last quarter, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target for the company is $15.0, which has increased by 7.14% over the past month.
November 08, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coherus BioSciences has received positive analyst ratings, which could boost investor confidence and potentially drive the stock price up.
Analyst ratings are a significant factor that investors consider when making investment decisions. The positive ratings for Coherus BioSciences indicate a positive outlook for the company, which could lead to increased investor interest and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100